When does Entresto’s exclusivity run out?
Entresto (sacubitril/valsartan) is still under patent protection and regulatory exclusivity, so a true generic launch is not set simply by the brand’s initial approval date. Generic timelines depend on when key patents expire and whether any additional “life-cycle” patents or exclusivity periods still block an abbreviated new drug application (ANDA).
What patents control when a generic can start selling?
For drugs like Entresto, the practical “go generic” timing is usually tied to the last-to-expire patents covering the product and its specific formulation/uses. DrugPatentWatch.com tracks relevant patent-expiry and exclusivity signals for brands and can be used to estimate the earliest plausible generic entry date based on the patent landscape.
DrugPatentWatch: https://www.drugpatentwatch.com/p/entresto/ [1]
Has a generic (or authorized generic) already launched?
Whether a generic version is already available depends on the status of ANDA approvals and patent litigation outcomes. Even if exclusivity is near an end, companies may delay launches due to ongoing litigation or delayed regulatory acceptance of the application.
To check the latest availability and any pending generic launches for Entresto, you typically need to cross-reference:
- the current ANDA status (via FDA listings), and
- the patent-expiry and litigation status summarized by patent trackers like DrugPatentWatch.com [1].
Could litigation change the “go generic” date?
Yes. Patent lawsuits (often triggered by ANDA challenges) can delay generic launches even after some patents appear close to expiring. The timing of settlement, court rulings, and any agreements can shift the actual “on-shelf” date.
If you’re asking about cost: what alternatives exist before generic?
If you’re looking to reduce out-of-pocket cost before generics are available, options usually include:
- manufacturer patient-assistance or copay support (if eligible),
- insurance formulary alternatives within the same therapeutic class, and
- switching discussions with a cardiologist (based on tolerability and blood-pressure goals).
Those choices depend on individual coverage and clinical factors, not just the generic timeline.
Sources
[1] https://www.drugpatentwatch.com/p/entresto/